(NASDAQ:VBIV) shares saw heavy trading volume with 422K shares changing hands on Tuesday. Trading volume was up 89.69% over the stocks average daily volume.
Short traders are feeling a little more bearish on the company if you take a look at the rise in short interest. The stock experienced a rise in short interest between September 29, 2017 and October 13, 2017 of 3.18%. Short interest increased 28,757 over that period. The short-interest ratio increased to 16.0 and the percentage of shorted shares is 0.04% as of October 13.
There has been some buying insider activity on VBI Vaccines, Inc. – Ordinary S (NASDAQ:VBIV) recently. Francisco Diaz-mitoma, Chief Medical Officer acquired $9,510 worth of shares at an average price of $3.17 on August 21st. Diaz-mitoma now owns $9,510 of stock per an SEC filing yesterday. Steven Gillis, Director reported the purchase of 300,000 shares of (VBIV). The shares were purchased at an average price of $3.05. Gillis now owns $9,229,474 of the stock according to the SEC filing.
Director Sam Chawla disclosed the purchase of 3,100,000 shares of VBIV stock. The shares were bought on October 30th for an average price of $3.05. The Director now owns $28,504,461 of the stock per the Form 4 SEC filing.
The company is trading unchanged by 0.00% percent from yesterday’s close. It is currently trading at $3.44 which is just a bit below $3.77, the 50 day moving average and which is well below the 200 day moving average of $4.53. The 50 day moving average was down $-0.33 or -8.77% whereas the 200 day average was down by -23.99%.
As of the last earnings report the EPS was $-0.87 and is estimated to be $-0.89 for the current year with 40,229,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.24 with next year’s EPS anticipated to be $-1.01.
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company’s commercial stage product is Sci-B-Vac, a third-generation licensed hepatitis B vaccine for adults, children, and newborn infants. It is also involved in CMV vaccine program, which is in Phase I clinical trials for the prevention of cytomegalovirus infection; GBM immunotherapy program, a preclinical stage glioblastoma multiforme therapeutic vaccine candidate; and RSV vaccine program, a discovery stage novel respiratory syncytial virus vaccine candidate. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts..